Year: 2015
Type: article
Abstract: Cancer is a disease characterized by unrestrained cellular proliferation. In order to sustain growth, cancer cells undergo a complex metabolic rearrangement characterized by changes in metabolic pathways involved in energy production and biosynthetic processes. The relevance of the metabolic transformation of cancer cells has been recently included in the updated version of the review "Hallmarks of Cancer", where dysregulation of cellular metabolism was included as an emerging hallmark. While several lines of evidence suggest that metabolic rewiring is orchestrated by the concerted action of oncogenes and tumor suppressor genes, in some circumstances altered metabolism can play a primary role in oncogenesis. Recently, mutations of cytosolic and mitochondrial enzymes involved in key metabolic pathways have been associated with hereditary and sporadic forms of cancer. Together, these results demonstrate that aberrant metabolism, once seen just as an epiphenomenon of oncogenic reprogramming, plays a key role in oncogenesis with the power to control both genetic and epigenetic events in cells. In this review, we discuss the relationship between metabolism and cancer, as part of a larger effort to identify a broad-spectrum of therapeutic approaches. We focus on major alterations in nutrient metabolism and the emerging link between metabolism and epigenetics. Finally, we discuss potential strategies to manipulate metabolism in cancer and tradeoffs that should be considered. More research on the suite of metabolic alterations in cancer holds the potential to discover novel approaches to treat it.
Source: Seminars in Cancer Biology
Authors: Matthew D. Hirschey, Ralph J. DeBerardinis, Anna Mae E. Diehl, Janice E. Drew, Christian Frezza, Michelle F. Green, Lee W. Jones, Young H. Ko, Anne Le, Michael A. Lea, Jason W. Locasale, Valter D. Longo, Costas A. Lyssiotis, Eoin McDonnell, Mahya Mehrmohamadi, Gregory Michelotti, Vinayak Muralidhar, Michael P. Murphy, Peter L. Pedersen, Brad Poore, Lizzia Raffaghello, Jeffrey C. Rathmell, Sharanya Sivanand, Matthew G. Vander Heiden, Kathryn E. Wellen
Institutions: Duke University, Duke Medical Center, Children's Medical Center, The University of Texas Southwestern Medical Center, University of Aberdeen, University of Cambridge, MRC Cancer Unit, Hutchison/MRC Research Centre, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Johns Hopkins Medicine, Rutgers, The State University of New Jersey, Rutgers New Jersey Medical School, Cornell University, University of Southern California, University of Michigan, Harvard University, Harvard–MIT Division of Health Sciences and Technology, Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology, MRC Mitochondrial Biology Unit, Wellcome Trust, Istituto Giannina Gaslini, University of Pennsylvania, Dana-Farber Cancer Institute
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $6,060
Funders: Purdue University, Wayne State University, Creighton University, Barbara Ann Karmanos Cancer Institute, University of Glasgow, Università degli Studi di Firenze, VIT University, National and Kapodistrian University of Athens, Nara Medical University, SASTRA University, National Technical University of Athens, University of Illinois at Urbana-Champaign, Medical Research Council, National Institute on Aging, National Cancer Institute
OpenAlex ID: W1940930637